TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
TG Therapeutics presented new MS portfolio data at MSToronto2026, headlined by seven-year BRIUMVI results showing 88.3% of continuously treated patients free from confirmed disability progression and a Year 7 annualized relapse rate of 0.018. Positive Phase 3 ENHANCE results met their primary endpoint, showing a single 600 mg Day 1 infusion is bioequivalent to the approved two-dose initiation regimen, while Phase 1 subcutaneous data (bioavailability >60%) support a quarterly dosing schedule in a fully enrolled Phase 3 trial.
Key figures
- Drug Name
- BRIUMVI (ublituximab-xiiy)
- Phase Of Trial
- Phase 3
- Azer cel presentation
- late-breaking oral, Oct 23, 2026
- Real world relapse free
- 99.2%
- Annualized relapse rate 7yr
- 0.018
- Subcutaneous bioavailability
- >60%
- Disability progression free 7yr
- 88.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.